bluebird bio, Inc., a biotechnology company listed on the US stock market under the ticker BLUE.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). The materials are related to a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. This filing, identified as DEFA14A, indicates that bluebird bio is providing additional information following a definitive proxy statement. The company has confirmed that no filing fee is required for this submission. The purpose of the filing is not specified in the provided text, but such documents typically relate to matters requiring shareholder votes, such as corporate governance issues, upcoming annual meetings, or special matters that require shareholder approval.

bluebird bio, Inc., a biotechnology company listed on the US stock market under the ticker BLUE.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). The materials are related to a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. This filing, identified as DEFA14A, indicates that bluebird bio is providing additional information following a definitive proxy statement. The company has confirmed that no filing fee is required for this submission. The purpose of the filing is not specified in the provided text, but such documents typically relate to matters requiring shareholder votes, such as corporate governance issues, upcoming annual meetings, or special matters that require shareholder approval.